Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.65), $0.15 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $15.9 million versus the consensus estimate of $16.5 million.

“The acceptance of our sNDAs by the FDA is an important step towards a potential new treatment option for patients living with bipolar depression, a condition with a limited number of approved treatments. While preparing for this significant opportunity, our team will continue to execute on our commercial objectives for CAPLYTA and advance our robust pipeline,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.